High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals

Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I

(2018) Najla Arshad et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies

(2018) Vanessa M. Tubb et al.   Journal for ImmunoTherapy of Cancer

Classification and Personalized Prognosis in Myeloproliferative Neoplasms

(2018) Jacob Grinfeld et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies

(2018) Uffe Klausen et al.   Frontiers in Immunology

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

(2017) M O Holmström et al.   LEUKEMIA

Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma

(2017) Julie S. Nielsen et al.   OncoImmunology

The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms

(2016) M O Holmström et al.   LEUKEMIA

Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm

(2016) Jen Chin Wang et al.   LEUKEMIA RESEARCH

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

(2014) A. Tefferi et al.   BLOOD

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms

(2014) P. Lundberg et al.   BLOOD

JAK2V617F andCALRmutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort

(2014) Gillian McGaffin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations

(2014) H. Andrikovics et al.   HAEMATOLOGICA

Calreticulin mutations and long-term survival in essential thrombocythemia

(2014) A Tefferi et al.   LEUKEMIA

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

(2014) A Tefferi et al.   LEUKEMIA

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes

(2013) E. Rumi et al.   BLOOD

HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients

(2013) S. Munir et al.   CANCER RESEARCH

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

(2012) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response definition criteria for ELISPOT assays revisited

(2010) Z. Moodie et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

BCR/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors

(2009) Sylvie Rusakiewicz et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY